DTG50mg+3TC300mg+TDF300mg tab/90 No CTN

General description:
Dolutegravir 50mg + Lamivudine 300mg + Tenofovir disoproxil fumarate 300mg tablets in a bottle pack of 90 without carton

Technical specifications:
Each tablet contains Dolutegravir 50mg + Lamivudine 300mg + Tenofovir disoproxil fumarate 300mg which is equivalent to 245mg of Tenofovir Disoproxil as fixed dose combination (FDC).

Therapeutic class:
Dolutegravir is an Integrase Inhibitor
Lamivudine is a Nucleoside Reverse Transcriptase Inhibitors (NRTI).
Tenofovir is a Nucleotide Reverse Transcriptase Inhibitor (NtRTI)

Indications:
Management of HIV infection in children and adults. Administration by mouth (oral), PO.

Guidelines for use
For more details, please click the links listed below:

http://www.who.int/hiv/pub/guidelines/en/

and

http://www.who.int/selection_medicines/list/en/

or your regional national guidelines

For details about paediatric dosage schemes, please click the links listed below:

http://www.who.int/hiv/topics/paediatric/en/

http://www.who.int/hiv/paediatric/generictool/en/


Shelf life:
24 months

Storage and transportation:
Do not store above 30ºC, protect from light.
Store in tightly closed original container.
Keep out of reach and sight of children.

Alternative products:
The product may also be available in other formulations, pack sizes, or in combinations with other ARVs